Performance of PCA3 and TMPRSS2:ERG urinary biomarkers in prediction of biopsy outcome in the Canary Prostate Active Surveillance Study (PASS)

Lisa F. Newcomb, Yingye Zheng, Anna V. Faino, Daniella Bianchi-Frias, Matthew R. Cooperberg, Marshall D. Brown, James D. Brooks, Atreya Dash, Michael D. Fabrizio, Martin E. Gleave, Michael Liss, Todd M. Morgan, Ian M. Thompson, Andrew A. Wagner, Peter R. Carroll, Peter S. Nelson, Daniel W. Lin

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

Background: For men on active surveillance for prostate cancer, biomarkers may improve prediction of reclassification to higher grade or volume cancer. This study examined the association of urinary PCA3 and TMPRSS2:ERG (T2:ERG) with biopsy-based reclassification. Methods: Urine was collected at baseline, 6, 12, and 24 months in the multi-institutional Canary Prostate Active Surveillance Study (PASS), and PCA3 and T2:ERG levels were quantitated. Reclassification was an increase in Gleason score or ratio of biopsy cores with cancer to ≥34%. The association of biomarker scores, adjusted for common clinical variables, with short- and long-term reclassification was evaluated. Discriminatory capacity of models with clinical variables alone or with biomarkers was assessed using receiver operating characteristic (ROC) curves and decision curve analysis (DCA). Results: Seven hundred and eighty-two men contributed 2069 urine specimens. After adjusting for PSA, prostate size, and ratio of biopsy cores with cancer, PCA3 but not T2:ERG was associated with short-term reclassification at the first surveillance biopsy (OR = 1.3; 95% CI 1.0–1.7, p = 0.02). The addition of PCA3 to a model with clinical variables improved area under the curve from 0.743 to 0.753 and increased net benefit minimally. After adjusting for clinical variables, neither marker nor marker kinetics was associated with time to reclassification in subsequent biopsies. Conclusions: PCA3 but not T2:ERG was associated with cancer reclassification in the first surveillance biopsy but has negligible improvement over clinical variables alone in ROC or DCA analyses. Neither marker was associated with reclassification in subsequent biopsies.

Original languageEnglish (US)
Pages (from-to)438-445
Number of pages8
JournalProstate Cancer and Prostatic Diseases
Volume22
Issue number3
DOIs
StatePublished - Sep 1 2019

ASJC Scopus subject areas

  • Oncology
  • Urology
  • Cancer Research

Fingerprint Dive into the research topics of 'Performance of PCA3 and TMPRSS2:ERG urinary biomarkers in prediction of biopsy outcome in the Canary Prostate Active Surveillance Study (PASS)'. Together they form a unique fingerprint.

  • Cite this

    Newcomb, L. F., Zheng, Y., Faino, A. V., Bianchi-Frias, D., Cooperberg, M. R., Brown, M. D., Brooks, J. D., Dash, A., Fabrizio, M. D., Gleave, M. E., Liss, M., Morgan, T. M., Thompson, I. M., Wagner, A. A., Carroll, P. R., Nelson, P. S., & Lin, D. W. (2019). Performance of PCA3 and TMPRSS2:ERG urinary biomarkers in prediction of biopsy outcome in the Canary Prostate Active Surveillance Study (PASS). Prostate Cancer and Prostatic Diseases, 22(3), 438-445. https://doi.org/10.1038/s41391-018-0124-z